Oricell Therapeutics, a Chinese biotech firm focused on cell therapies for cancer, has raised $40 million in a new financing round. The company describes this as a pre-IPO funding event. This latest capital infusion brings its total raised in this recent financing series to more than $110 million.
The Shanghai-based company is developing CAR-T therapies designed to treat solid tumors, a significant technical challenge in the field of oncology. Its lead candidate targets the GPC3 protein for a specific type of liver cancer. Advancing these complex, personalized cell therapies through clinical trials requires substantial financial resources.